TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 11389575
Drug: Salbutamol (SB),
Approvals — FDA: no, EMA: no, PMDA: no
Description: Salbutamol (SB), max. 2.5 mg
Study: 11389575
Drug: Ipratropium bromide
Normalized name: Ipratropium Bromide
DrugBank: Ipratropium (DB00332)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Ipratropium bromide (IB), max. 0.5 mg
Study: 7633556
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of Salbutamol and Ipratropium bromide
Study: 9431826
Drug: Buffered ketoprofen
Normalized name: Ketoprofen
DrugBank: Ketoprofen (DB01009)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Buffered ketoprofen (25 mg)
Study: 9431826
Drug: Unbuffered ketoprofen
Normalized name: Ketoprofen
DrugBank: Ketoprofen (DB01009)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Unbuffered ketoprofen (12.5 mg)
Study: 9431826
Drug: Unbuffered ketoprofen
Normalized name: Ketoprofen
DrugBank: Ketoprofen (DB01009)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Unbuffered ketoprofen (25 mg)
Study: 3566996
Drug: Naloxone 2
Normalized name: naloxone 2 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Naloxone 2 mg, i.v. during surgery
Study: 31532137
Drug: Thread-embedding therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Thread-embedding therapy in addition to routine rehabilitation treatment (physical therapy, spleen-strengthening, kidney-nourishing, Governor Vessel-regulating massage, vibroacoustic therapy, and scalp acupuncture), applied at acupoints (LI15, SJ14, SI11, ST25, C4, L1, L4), 6-8 acupoints selected each time, once a week for 4 weeks, with 3 courses total.
Study: 31532137
Drug: Routine rehabilitation
Normalized name: Peace Out Acne Hero Routine KIT
Approvals — FDA: no, EMA: no, PMDA: no
Description: Routine rehabilitation treatment (physical therapy, spleen-strengthening, kidney-nourishing, Governor Vessel-regulating massage, vibroacoustic therapy, and scalp acupuncture).
Study: 23641817
Drug: Lung Support
Normalized name: beef lung preparation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lung Support Formula (1 capsule twice a day for 12 weeks)
Study: 23641817
Drug: Placebo (1
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo (1 capsule twice a day for 12 weeks)
Study: 21341922
Drug: Brief behaviorally
Normalized name: ethanol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Brief behaviorally based smoking-cessation treatment
Study: 11702100
Drug: Alteplase 100
Normalized name: alteplase 100 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Alteplase 100 mg (5 patients)
Study: 11702100
Drug: Heparin 1,750
Approvals — FDA: no, EMA: no, PMDA: no
Description: Heparin 1,750 IU/h (2 patients)
Study: 9131360
Drug: Professionally led
Normalized name: Clearskin Professional Daily Correcting
DrugBank: Salicylic acid (DB00936)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Professionally led support group intervention combining group therapy techniques with psychoeducational strategies in six weekly sessions
Study: 7964860
Drug: Intravenous high-dose
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous high-dose immunoglobulins
Study: 7964860
Drug: GTOE supplementation
Approvals — FDA: no, EMA: no, PMDA: no
Description: GTOE supplementation therapy
Study: 31301533
Drug: Benzathine penicillin
Normalized name: Benzathine penicillin G
Approvals — FDA: no, EMA: no, PMDA: no
Description: Benzathine penicillin G (BPG) administered every 4 weeks
Study: 28567555
Drug: e‐PROMs questionnaire
Approvals — FDA: no, EMA: no, PMDA: no
Description: e‐PROMs questionnaire (completed online on a monthly basis for 12 months)
Study: 19842940
Drug: Genotype-guided dosing
Normalized name: dengue virus live antigen, CYD serotype 1 / dengue virus live antigen, CYD serotype 2 / dengue virus live antigen, CYD serotype 3 / dengue virus live antigen, CYD serotype 4 Injection [Dengvaxia]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Genotype-guided dosing of coumarin derivatives
Study: 19842940
Drug: Standard dosing
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard dosing of coumarin derivatives (control group not explicitly mentioned)
Study: 10972632
Drug: valsartan 80
Normalized name: valsartan 80 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: valsartan 80 mg once daily for 4 weeks, then titrated to 160 mg once daily for an additional 4 weeks
Study: 8829024
Drug: Ticlopidine hydrochloride
Normalized name: Ticlopidine Hydrochloride
DrugBank: Ticlopidine (DB00208)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Ticlopidine hydrochloride 200 mg once daily and nicardipine hydrochloride 20 mg three times daily (TID)
Study: 8829024
Drug: Ticlopidine hydrochloride
Normalized name: Ticlopidine Hydrochloride
DrugBank: Ticlopidine (DB00208)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Ticlopidine hydrochloride 200 mg once daily
Study: 8829024
Drug: Aspirin 81
Normalized name: aspirin 81 MG
DrugBank: Acetylsalicylic acid (DB00945)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Aspirin 81 mg once daily and nicardipine hydrochloride 20 mg TID
Study: 6111331
Drug: 40 mg
Normalized name: rutin 40 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 40 mg betaxolol
Study: 23149503
Drug: Narrow body
Approvals — FDA: no, EMA: no, PMDA: no
Description: Narrow body implants (NBIs) with 2.2‐ or 2.4‐mm diameter
Study: 20638454
Drug: Aluminum-adjuvated split-virion
Approvals — FDA: no, EMA: no, PMDA: no
Description: Aluminum-adjuvated split-virion vaccine (10 or 15 microg) in children aged 3-11 years
Study: 20638454
Drug: Aluminum-adjuvated split-virion
Approvals — FDA: no, EMA: no, PMDA: no
Description: Aluminum-adjuvated split-virion vaccine (30 microg) in children aged 12-17 years
Study: 20638454
Drug: Aluminum-adjuvated whole-virion
Normalized name: Whole-Virion Inactivated SARS-CoV-2 Vaccine
DrugBank: BBV152 (DB15847)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Aluminum-adjuvated whole-virion vaccine (5 microg) in children aged 12-17 years
Study: 20638454
Drug: Aluminum-adjuvated split-virion
Approvals — FDA: no, EMA: no, PMDA: no
Description: Aluminum-adjuvated split-virion vaccine (5-30 microg) in children aged 12-17 years
Study: 20638454
Drug: Aluminum-adjuvated split-virion
Approvals — FDA: no, EMA: no, PMDA: no
Description: Aluminum-adjuvated split-virion vaccine (5-15 microg) in children aged 3-11 years
Study: 18339115
Drug: Topiramate (up
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topiramate (up to 200 mg daily in divided doses)
Study: 15814029
Drug: Mefloquine alone
Approvals — FDA: no, EMA: no, PMDA: no
Description: Mefloquine alone (25 mg/kg single dose)
Study: 15814029
Drug: Artesunate followed
Normalized name: Artesunate
DrugBank: Artesunate (DB09274)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Artesunate followed by mefloquine (4 mg/kg/day for 3 days followed by 15 mg/kg on day 3)
Study: 12414332
Drug: Sildenafil (50
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sildenafil (50 mg, adjustable to 25 mg or 100 mg)
Study: 12414332
Drug: Sildenafil (50
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sildenafil (50 mg, adjustable to 25 mg or 100 mg) and Placebo
Study: 1612530
Drug: Intranasal salmon
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intranasal salmon calcitonin (SCT) 100 IU daily plus calcium 500 mg daily
Study: 1612530
Drug: Intranasal salmon
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intranasal salmon calcitonin (SCT) 100 IU daily for alternate cycles of 2 months with a 1‐month interval plus calcium 500 mg daily
Study: 1612530
Drug: Intranasal salmon
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intranasal salmon calcitonin (SCT) 100 IU daily for alternate cycles of 3 months of treatment followed by a 3‐month interval plus calcium 500 mg daily
Study: 1612530
Drug: Calcium 500
Normalized name: Calcium 500+D
Approvals — FDA: no, EMA: no, PMDA: no
Description: Calcium 500 mg daily alone (control group)
Study: 6423316
Drug: Oral disodium
Normalized name: etidronate disodium Oral Tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral disodium cromoglycate (DSCG) at a dose of 100 mg/kg/day in four divided doses for 6 months
Study: 30001288
Drug: Colonoscopic enema
Approvals — FDA: no, EMA: no, PMDA: no
Description: Colonoscopic enema of 1 L polyethylene glycol (PEG)
Study: 30001288
Drug: Additional oral
Normalized name: chromous chloride
Approvals — FDA: no, EMA: no, PMDA: no
Description: Additional oral intake of 2 L polyethylene glycol (PEG)
Study: 30001288
Drug: Colonoscopic enema
Approvals — FDA: no, EMA: no, PMDA: no
Description: Colonoscopic enema of 1 L PEG
Study: 30317015
Drug: Individually supervised
Normalized name: chloroxylenol
DrugBank: Chloroxylenol (DB11121)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Individually supervised physiotherapy treatment
Study: 22044694
Drug: Polyphenon E
Normalized name: Polyphenon E
DrugBank: Sinecatechins (DB01266)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Polyphenon E (800 mg epigallocatechin gallate)
Study: 17033900
Drug: 75,000 SQ-T
Approvals — FDA: no, EMA: no, PMDA: no
Description: 75,000 SQ-T grass allergen tablets
Study: 9289913
Drug: Polyvitamin pills
Approvals — FDA: no, EMA: no, PMDA: no
Description: Polyvitamin pills 'Duovit'
Study: 9289913
Drug: Supplement of
Normalized name: OIL OF CAMPHOR
Approvals — FDA: no, EMA: no, PMDA: no
Description: Supplement of third dishes with vitamin C
Study: 8501579
Drug: Didanosine 120
Approvals — FDA: no, EMA: no, PMDA: no
Description: Didanosine 120 mg/m2 per day
Study: 8501579
Drug: Didanosine 270
Approvals — FDA: no, EMA: no, PMDA: no
Description: Didanosine 270 mg/m2 per day
Study: 2892517
Drug: Sufentanil 5
Normalized name: SUFentanil 50 MCG in 1 ML Injection
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sufentanil 5 micrograms/ml
Study: 2783184
Drug: Mexiprostil 800
Approvals — FDA: no, EMA: no, PMDA: no
Description: Mexiprostil 800 micrograms (tablet and capsule)
Study: 2783184
Drug: Mexiprostil 1200
Approvals — FDA: no, EMA: no, PMDA: no
Description: Mexiprostil 1200 micrograms (tablet and capsule)
Study: 2783184
Drug: Mexiprostil (both
Approvals — FDA: no, EMA: no, PMDA: no
Description: Mexiprostil (both doses and formulations)
Study: 4909818
Drug: Duogastrone capsules,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Duogastrone capsules, one four times daily, half-an-hour before meals
Study: 31958337
Drug: Letrozole (Lz)
Normalized name: Letrozole
DrugBank: Letrozole (DB01006)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Letrozole (Lz) 2.5 mg/day
Study: 31958337
Drug: Testosterone (T)
Normalized name: Testosterone
DrugBank: (1,2,6,7-3H)Testosterone (DB14093)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Testosterone (T) 1 mg/kg/month
Study: 19679277
Drug: Treatment targeting
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Treatment targeting increased neuronal hyperexcitability
Study: 17039215
Drug: Suprascapular nerve
Normalized name: nerve growth factor
DrugBank: Nerve Growth Factor (DB12620)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Suprascapular nerve block (SSNB) plus standard rehabilitation treatment (Group A)
Study: 17039215
Drug: Standard rehabilitation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard rehabilitation treatment alone (Group B)
Study: 14676787
Drug: High-dose intravenous
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-dose intravenous melphalan and autologous stem cell transplantation (HDM/SCT) as initial therapy (Arm-1)
Study: 14676787
Drug: High-dose intravenous
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-dose intravenous melphalan and autologous stem cell transplantation (HDM/SCT) following two cycles of oral melphalan and prednisone (Arm-2)
Study: 11303137
Drug: Enteral fluconazole
Normalized name: Fluconazole
DrugBank: Fluconazole (DB00196)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Enteral fluconazole 400 mg per day
Study: 9283994
Drug: Colloidal silicic
Normalized name: silicic acid
DrugBank: Silicic acid (DB14138)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Colloidal silicic acid gel, orally and topically, 30 ml daily for 3 months
Study: 9283994
Drug: Placebo gel,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo gel, orally and topically, identical treatment as the intervention group
Study: 7687592
Drug: Active medication
Normalized name: Activated Charcoal
DrugBank: Activated charcoal (DB09278)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Active medication 1
Study: 7687592
Drug: Active medication
Normalized name: Activated Charcoal
DrugBank: Activated charcoal (DB09278)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Active medication 2
Study: 3752487
Drug: Thiopentone (3
Approvals — FDA: no, EMA: no, PMDA: no
Description: Thiopentone (3 mg/kg)
Study: 3752487
Drug: Thiopentone (6
Approvals — FDA: no, EMA: no, PMDA: no
Description: Thiopentone (6 mg/kg)
Study: 33455
Drug: Methohexitone (1
Approvals — FDA: no, EMA: no, PMDA: no
Description: Methohexitone (1 mg/kg)
Study: 29336718
Drug: Irvingia gabonensis
Normalized name: IRVINGIA GABONENSIS SEED
Approvals — FDA: no, EMA: no, PMDA: no
Description: Irvingia gabonensis (150 mg) twice a day for 90 days
Study: 27679518
Drug: Patiromer 25.2
Normalized name: patiromer 25.2 GM Powder for Oral Suspension
Approvals — FDA: no, EMA: no, PMDA: no
Description: Patiromer 25.2 g/d
Study: 27679518
Drug: Patiromer (dosing
Approvals — FDA: no, EMA: no, PMDA: no
Description: Patiromer (dosing regimen study)
Study: 17971713
Drug: ATV300/RTV (Atazanavir
Approvals — FDA: no, EMA: no, PMDA: no
Description: ATV300/RTV (Atazanavir 300 mg with Ritonavir 100 mg)
Study: 17971713
Drug: ATV400 (Atazanavir
Approvals — FDA: no, EMA: no, PMDA: no
Description: ATV400 (Atazanavir 400 mg)
Study: 17180590
Drug: roxithromycin (300
Approvals — FDA: no, EMA: no, PMDA: no
Description: roxithromycin (300 mg per day)
Study: 8296384
Drug: High-titre Edmonston-Zagreb
Normalized name: high-density polyethylene
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-titre Edmonston-Zagreb (EZ) measles vaccine administered at 5 months
Study: 8296384
Drug: High-titre Schwarz
Normalized name: high-density polyethylene
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-titre Schwarz (SW-HT) measles vaccine administered at 5 months
Study: 8296384
Drug: Standard Schwarz
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard Schwarz (SW-std) measles vaccine administered at 10 months
Study: 8296384
Drug: Placebo administered
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo administered at 5 months
Study: 3443142
Drug: Propranolol 80
Normalized name: propranolol 80 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Propranolol 80 mg twice daily with omeprazole 20 mg
Study: 3443142
Drug: Propranolol 80
Normalized name: propranolol 80 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Propranolol 80 mg twice daily with placebo
Study: 31658396
Drug: HL2351 (1,
Approvals — FDA: no, EMA: no, PMDA: no
Description: HL2351 (1, 2, 4, 8 and 12 mg/kg)
Study: 31658396
Drug: Anakinra (100
Approvals — FDA: no, EMA: no, PMDA: no
Description: Anakinra (100 mg)
Study: 25686055
Drug: Antioxidant supplement
Normalized name: antioxidant 119
Approvals — FDA: no, EMA: no, PMDA: no
Description: Antioxidant supplement (Group A) - pycnogenol 50 mg, Vitamin E 30 mg, coenzyme Q10 20 mg
Study: 22251879
Drug: Immediate implant
Normalized name: IR-3535
Approvals — FDA: no, EMA: no, PMDA: no
Description: Immediate implant treatment (IIT)
Study: 22251879
Drug: Conventional implant
Approvals — FDA: no, EMA: no, PMDA: no
Description: Conventional implant treatment (CIT)
Study: 22251879
Drug: Grafted implant
Normalized name: polyvinyl alcohol graft polyethylene glycol copolymer (3:1; 45000 MW)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Grafted implant treatment (GIT)
Study: 18463848
Drug: Standard care
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard care plus extracorporeal therapy with PMX-B
Study: 16243418
Drug: Cyamemazine (25-50
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cyamemazine (25-50 mg q.d.)
Study: 16243418
Drug: Bromazepam (3-6
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bromazepam (3-6 mg q.d.)
Study: 11103484
Drug: Morphine-bupivacaine combination
Normalized name: morphine, combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Morphine-bupivacaine combination
Study: 29438271
Drug: 200 μg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 200 μg of misoprostol
Study: 25801339
Drug: Immediate loading
Approvals — FDA: no, EMA: no, PMDA: no
Description: Immediate loading of implants (test group)
Study: 25801339
Drug: Unloaded implants
Approvals — FDA: no, EMA: no, PMDA: no
Description: Unloaded implants for 3 months (control group)
Study: 25801339
Drug: Implants with
Normalized name: Primatene with ephedrine Pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: Implants with TiUnite surface (AOX)
Study: 25801339
Drug: Implants with
Normalized name: Primatene with ephedrine Pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: Implants with machine-milled surface (AM)
Study: 25801339
Drug: Implants at
Normalized name: rose bengal AT
Approvals — FDA: no, EMA: no, PMDA: no
Description: Implants at implant level (IL)
Study: 25801339
Drug: Overall implant
Approvals — FDA: no, EMA: no, PMDA: no
Description: Overall implant survival rate
Study: 22343483
Drug: Moderate-dose MPH
Normalized name: MPH
DrugBank: Methylphenidate (DB00422)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Moderate-dose MPH
Study: 22343483
Drug: Low-dose MPH
Normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Low-dose MPH
Study: 20509332
Drug: Alpha-tocopherol (Vitamin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Alpha-tocopherol (Vitamin E) 200 mg/day for 21 days
Study: 15196143
Drug: Stellate ganglion
Normalized name: Mastocarpus stellatus extract
Approvals — FDA: no, EMA: no, PMDA: no
Description: Stellate ganglion near-infrared irradiation (SGR) once weekly for 4 weeks
Study: 9794094
Drug: 17 mmol/d
Approvals — FDA: no, EMA: no, PMDA: no
Description: 17 mmol/d Mg orotate
Study: 8637449
Drug: Thyrotropin (TSH)‐releasing
Approvals — FDA: no, EMA: no, PMDA: no
Description: Thyrotropin (TSH)‐releasing hormone (TRH)
Study: 8637449
Drug: Gonadotropin‐releasing hormone
Approvals — FDA: no, EMA: no, PMDA: no
Description: Gonadotropin‐releasing hormone (GnRH)
Study: 8637449
Drug: Ovine corticotropin
Normalized name: Ovine corticotropin-releasing factor
DrugBank: Corticorelin ovine triflutate (DB09067)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ovine corticotropin (ACTH)‐releasing hormone (oCRH)
Study: 8637449
Drug: Human growth
Normalized name: Human growth hormone
DrugBank: Somatotropin (DB00052)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Human growth hormone‐(GH)‐releasing hormone (hGHRH)
Study: 7297143
Drug: 0.4 mg
Normalized name: biotin 0.4 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.4 mg pindolol
Study: 7416612
Drug: Inhaled isoproterenol
Normalized name: isoproterenol Inhalation Solution
Approvals — FDA: no, EMA: no, PMDA: no
Description: Inhaled isoproterenol
Study: 12011527
Drug: Povidone iodine
Normalized name: POVIDONE IODINE
DrugBank: Povidone-iodine (DB06812)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Povidone iodine suppositories
Study: 12011527
Drug: Lactobacilli capsules
Normalized name: lactobacillic acid
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lactobacilli capsules
Study: 10465068
Drug: rgp160 IIIB
Approvals — FDA: no, EMA: no, PMDA: no
Description: rgp160 IIIB vaccine
Study: 7494809
Drug: Deflazacort (30
Approvals — FDA: no, EMA: no, PMDA: no
Description: Deflazacort (30 mg)
Study: 7494809
Drug: Methylprednisolone (20
Approvals — FDA: no, EMA: no, PMDA: no
Description: Methylprednisolone (20 mg)
Study: 2882966
Drug: Prednisolone (25
Approvals — FDA: no, EMA: no, PMDA: no
Description: Prednisolone (25 mg)
Study: 2185791
Drug: Nicardipine (2.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nicardipine (2.5 mg/h, increasing in steps of 2.5 mg/h at 2 h intervals, maximum rate 7.5 mg/h)
Study: 31731005
Drug: Tropifexor (TXR)
Normalized name: Tropifexor
DrugBank: Tropifexor (DB16343)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tropifexor (TXR) 140 μg once daily
Study: 31731005
Drug: Cenicriviroc (CVC)
Normalized name: salicylic acid
DrugBank: Cenicriviroc (DB11758)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cenicriviroc (CVC) 150 mg once daily
Study: 31731005
Drug: Tropifexor (TXR)
Normalized name: Tropifexor
DrugBank: Tropifexor (DB16343)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tropifexor (TXR) 140 μg once daily + Cenicriviroc (CVC) 150 mg once daily
Study: 31731005
Drug: Tropifexor (TXR)
Normalized name: Tropifexor
DrugBank: Tropifexor (DB16343)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tropifexor (TXR) 90 μg once daily + Cenicriviroc (CVC) 150 mg once daily
Study: 31731005
Drug: Combination therapy
Normalized name: REGN10933+REGN10987 combination therapy
DrugBank: Anti-SARS-CoV-2 REGN-COV2 (DB15691)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination therapy (TXR + CVC)
Study: 31093755
Drug: 1 g
Normalized name: Molds 1 g
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1 g metformin every 12 hours for five consecutive days
Study: 27879195
Drug: Test formulation
Normalized name: mumps skin test antigen
Approvals — FDA: no, EMA: no, PMDA: no
Description: Test formulation of baclofen 10 mg
Study: 27879195
Drug: Reference formulation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Reference formulation of baclofen 10 mg
Study: 27879195
Drug: Comparison of
Normalized name: OIL OF CAMPHOR
Approvals — FDA: no, EMA: no, PMDA: no
Description: Comparison of test to reference formulation
Study: 16626571
Drug: Intracoronary PBSCs
Normalized name: HELIUM 992 mL in 1 L INTRACORONARY GAS
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intracoronary PBSCs transplantation following G-CSF mobilization (300-600 microg/day for 5 days)
Study: 16626571
Drug: Intracoronary PBSCs
Normalized name: HELIUM 992 mL in 1 L INTRACORONARY GAS
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intracoronary PBSCs transplantation following G-CSF mobilization
Study: 16626571
Drug: Standard therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard therapy (standard drug therapy and PCI)
Study: 9753961
Drug: Fentanyl 0.1
Normalized name: fentanyl 0.1 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fentanyl 0.1 mg 3 min prior to propofol
Study: 9753961
Drug: Lidocaine 40
Normalized name: lidocaine 400 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lidocaine 40 mg added to 200 mg propofol
Study: 9753961
Drug: Fentanyl 0.1
Normalized name: fentanyl 0.1 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fentanyl 0.1 mg 3 min prior to propofol mixed with lidocaine 40 mg
Study: 9753961
Drug: Injection via
Normalized name: vial,empty INJECTION VIAL (EA)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Injection via the forearm vein
Study: 2497096
Drug: Oxaprozin 600
Normalized name: oxaprozin 600 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oxaprozin 600 mg/day
Study: 30585904
Drug: Daily caffeine
Normalized name: Caffeine
DrugBank: Caffeine (DB00201)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Daily caffeine intake
Study: 15256687
Drug: Mixture of
Normalized name: OCTADECANOL (MIXTURE OF ISOMERS)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Mixture of whey protein (17.5 g), amino acids (4.9 g), and carbohydrates (77.4 g) (PAAC)
Study: 15256687
Drug: Isoenergetic carbohydrates
Normalized name: CARBOHYDRATE
Approvals — FDA: no, EMA: no, PMDA: no
Description: Isoenergetic carbohydrates (100 g) (CON)
Study: 9137476
Drug: D‐galactose (1.9
Approvals — FDA: no, EMA: no, PMDA: no
Description: D‐galactose (1.9 g/kg BW and day)